Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
ANNXBRISBANE, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on January 9, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
ANNXBRISBANE, Calif., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on December 10, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).
Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
ANNXBRISBANE, Calif., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the body, brain, and eye, today announced that it has granted inducement to a new non-executive employee under the terms of the 2022 Employment Inducement Award Plan. The equity award was approved on August 11, 2025, in accordance with Nasdaq Listing Rule 5635(c)(4).
Annexon Selected by EMA to Participate in Product Development Coordinator Pilot for Vonaprument (ANX007) for Dry Age-Related Macular Degeneration with Geographic Atrophy
ANNXNew Pilot Appoints Designated Product Development Coordinator to Navigate Regulatory Interactions, Respond to Ad-hoc Queries, and Support Evidence Planning
Annexon Presents Data Highlighting Outcomes With Tanruprubart At 2025 Peripheral Nerve Society Annual Meeting
ANNXCoinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday
ANNXHC Wainwright & Co. Maintains Buy on Annexon, Lowers Price Target to $14
ANNXNeedham Maintains Buy on Annexon, Lowers Price Target to $11
ANNXAnnexon Q1 EPS $(0.37) Misses $(0.29) Estimate
ANNXAnnexon's Investigational Drug Shows Rapid Recovery And Durable Benefit In Rare Neurological Disorder
ANNXAnnexon's tanruprubart showed significant and sustained functional gains in Guillain-Barré patients, meeting key Phase 3 trial endpoints.
Annexon Says Tanruprubart Met The Primary Endpoint; Demonstrates Rapid, Durable Recovery and Superior Efficacy In First Placebo-Controlled Phase 3 GBS Trial, Showing Significant Improvement In Motor Function, Mobility, and Disability Measures Over Placebo
ANNXAnnexon To Present Pivotal Data On First Potential Targeted Therapy For Guillain-Barré Syndrome And Showcases New GBS Education Campaign At AAN 2025 Annual Meeting
ANNXReported Earlier, Annexon Spotlights First-in-Class ANX005 Phase 3 Results For GBS And Launches 'Move GBS Forward' Initiative At AAN
ANNXNeedham Reiterates Buy on Annexon, Maintains $16 Price Target
ANNXAnnexon Q4 EPS $(0.33) vs $(0.36) YoY
ANNXAnnexon Presents ANX007 In Geographic Atrophy At Macula Society 48th Annual Meeting
ANNXAnnexon Announces 2025 Outlook, ANX005 Targets Guillain-Barré Syndrome BLA In H1 2025, ANX007 Completes Phase 3 Enrollment For Geographic Atrophy In H2 2025, ANX1502 Seeks Clinical Data In Q1 2025; Cash Runway Extends To H2 2026
ANNXCantor Fitzgerald Reiterates Overweight on Annexon
ANNXHC Wainwright & Co. Reiterates Buy on Annexon, Maintains $30 Price Target
ANNXNeedham Reiterates Buy on Annexon, Maintains $16 Price Target
ANNXAnnexon Q3 EPS $(0.25) Beats $(0.31) Estimate
ANNXBTIG Initiates Coverage On Annexon with Buy Rating, Announces Price Target of $15
ANNX